Implantica's RefluxStop Study Shows Strong Safety Profile in 602-Patient Trial
Event summary
- Implantica published a 602-patient real-world study on RefluxStop in Nature's Scientific Reports, with up to 6.75-year follow-up.
- Study showed >98% of patients had no serious safety issues requiring reoperation.
- Primary reason for reoperation (1.33%) was recurrence of hiatal hernia, significantly lower than standard surgical procedures.
- Results presented at 2025 American Foregut Society Meeting generated strong U.S. expert interest ahead of potential FDA approval.
The big picture
This study represents a significant validation of Implantica's RefluxStop technology, potentially disrupting the $3B+ anti-reflux market. The results come at a critical juncture as the company prepares for FDA approval, positioning it to challenge traditional surgical approaches with a device that addresses the root cause of acid reflux without encircling the food passageway. The strong safety profile could be a key differentiator in winning over both physicians and patients.
What we're watching
- Regulatory Pathway
- The pace at which Implantica secures FDA approval for U.S. market entry following this positive study.
- Market Adoption
- Whether the strong safety profile will accelerate physician and patient adoption in Europe and globally.
- Competitive Positioning
- How these results position RefluxStop against standard surgical options and other anti-reflux treatments.
Our editorial coverage: